

12
20. (NEW). The DNA construct according to claim 19, wherein the promoter comprises a CMV promoter.

21. (NEW). The method of claim 15, further comprising selecting for a cell, which has been infected or transduced by the retroviral vector.

22. (NEW). An *in vitro* method for infecting or transducing a target cell with a retroviral vector; the method comprising:

- (i) providing the target cell;
- (ii) contacting the cell with a retroviral vector,
 - (a) the retroviral vector comprising a packagable RNA genome;
 - (A) wherein when in the form of a DNA provirus, the retroviral vector is inserted into a target cell genome;
 - (B) said RNA genome carrying sequences which provide in the DNA provirus at least one selected gene capable of being expressed in the target cell and located within an intron in a transcription unit of the provirus;
which transcription unit further comprises a polynucleotide response element responsive to a nucleus to cytoplasm transport factor; and
- (iii) selecting for a cell which has been infected or transduced by the retroviral vector.

23. (NEW). Target cells resulting from the method according to claim 22.

REMARKS

Applicants have received and reviewed an Office Action dated November 15, 2000. By way of response, Applicants have canceled claim 11, amended claim 15, and presented new claims 19-23. Claims 1-10 and 12-23 are pending in this application. No new matter is added. Applicants submit the amended and newly presented claims are supported by the specification.